The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cancer Pain Therapeutics Market Research Report 2025
Synopsis
Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostic procedures or from skin, nerve, and the other changes caused by a hormone imbalance or immune response.
The global Cancer Pain Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Cancer Pain Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Pain Therapeutics.
Report Scope
The Cancer Pain Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Pain Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Pain Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BioDelivery Science
ProStrakan Group
Teva pharmaceuticals
Eli-Lilly
Grunenthal Group
GW Pharmaceuticals
Johnson＆Johnson
Meda Pharmaceuticals
Orexo
Sanofi
WEX Pharmaceuticals
Segment by Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
Segment by Application
Paracetamol Treatment-Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cancer Pain Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cancer Pain Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostic procedures or from skin, nerve, and the other changes caused by a hormone imbalance or immune response.
The global Cancer Pain Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Cancer Pain Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Pain Therapeutics.
Report Scope
The Cancer Pain Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Pain Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Pain Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BioDelivery Science
ProStrakan Group
Teva pharmaceuticals
Eli-Lilly
Grunenthal Group
GW Pharmaceuticals
Johnson＆Johnson
Meda Pharmaceuticals
Orexo
Sanofi
WEX Pharmaceuticals
Segment by Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
Segment by Application
Paracetamol Treatment-Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cancer Pain Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cancer Pain Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Cancer Pain Therapeutics Market Overview
1.1 Product Overview and Scope of Cancer Pain Therapeutics
1.2 Cancer Pain Therapeutics Segment by Type
1.2.1 Global Cancer Pain Therapeutics Market Value Comparison by Type (2024-2030)
1.2.2 Opioids
1.2.3 Non-Steroidal Anti-Inflammatory Drugs
1.2.4 Others
1.3 Cancer Pain Therapeutics Segment by Application
1.3.1 Global Cancer Pain Therapeutics Market Value by Application: (2024-2030)
1.3.2 Paracetamol Treatment-Related Immunotherapy
1.3.3 Radiotherapy
1.3.4 Chemotherapy
1.3.5 Hormone Therapy
1.4 Global Cancer Pain Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Cancer Pain Therapeutics Revenue 2019-2030
1.4.2 Global Cancer Pain Therapeutics Sales 2019-2030
1.4.3 Global Cancer Pain Therapeutics Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Cancer Pain Therapeutics Market Competition by Manufacturers
2.1 Global Cancer Pain Therapeutics Sales Market Share by Manufacturers (2019-2024)
2.2 Global Cancer Pain Therapeutics Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Cancer Pain Therapeutics Average Price by Manufacturers (2019-2024)
2.4 Global Cancer Pain Therapeutics Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Cancer Pain Therapeutics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cancer Pain Therapeutics, Product Type & Application
2.7 Cancer Pain Therapeutics Market Competitive Situation and Trends
2.7.1 Cancer Pain Therapeutics Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cancer Pain Therapeutics Players Market Share by Revenue
2.7.3 Global Cancer Pain Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cancer Pain Therapeutics Retrospective Market Scenario by Region
3.1 Global Cancer Pain Therapeutics Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Cancer Pain Therapeutics Global Cancer Pain Therapeutics Sales by Region: 2019-2030
3.2.1 Global Cancer Pain Therapeutics Sales by Region: 2019-2024
3.2.2 Global Cancer Pain Therapeutics Sales by Region: 2025-2030
3.3 Global Cancer Pain Therapeutics Global Cancer Pain Therapeutics Revenue by Region: 2019-2030
3.3.1 Global Cancer Pain Therapeutics Revenue by Region: 2019-2024
3.3.2 Global Cancer Pain Therapeutics Revenue by Region: 2025-2030
3.4 North America Cancer Pain Therapeutics Market Facts & Figures by Country
3.4.1 North America Cancer Pain Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Cancer Pain Therapeutics Sales by Country (2019-2030)
3.4.3 North America Cancer Pain Therapeutics Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Cancer Pain Therapeutics Market Facts & Figures by Country
3.5.1 Europe Cancer Pain Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Cancer Pain Therapeutics Sales by Country (2019-2030)
3.5.3 Europe Cancer Pain Therapeutics Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cancer Pain Therapeutics Market Facts & Figures by Country
3.6.1 Asia Pacific Cancer Pain Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Cancer Pain Therapeutics Sales by Country (2019-2030)
3.6.3 Asia Pacific Cancer Pain Therapeutics Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Cancer Pain Therapeutics Market Facts & Figures by Country
3.7.1 Latin America Cancer Pain Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Cancer Pain Therapeutics Sales by Country (2019-2030)
3.7.3 Latin America Cancer Pain Therapeutics Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cancer Pain Therapeutics Market Facts & Figures by Country
3.8.1 Middle East and Africa Cancer Pain Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Cancer Pain Therapeutics Sales by Country (2019-2030)
3.8.3 Middle East and Africa Cancer Pain Therapeutics Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Cancer Pain Therapeutics Sales by Type (2019-2030)
4.1.1 Global Cancer Pain Therapeutics Sales by Type (2019-2024)
4.1.2 Global Cancer Pain Therapeutics Sales by Type (2025-2030)
4.1.3 Global Cancer Pain Therapeutics Sales Market Share by Type (2019-2030)
4.2 Global Cancer Pain Therapeutics Revenue by Type (2019-2030)
4.2.1 Global Cancer Pain Therapeutics Revenue by Type (2019-2024)
4.2.2 Global Cancer Pain Therapeutics Revenue by Type (2025-2030)
4.2.3 Global Cancer Pain Therapeutics Revenue Market Share by Type (2019-2030)
4.3 Global Cancer Pain Therapeutics Price by Type (2019-2030)
5 Segment by Application
5.1 Global Cancer Pain Therapeutics Sales by Application (2019-2030)
5.1.1 Global Cancer Pain Therapeutics Sales by Application (2019-2024)
5.1.2 Global Cancer Pain Therapeutics Sales by Application (2025-2030)
5.1.3 Global Cancer Pain Therapeutics Sales Market Share by Application (2019-2030)
5.2 Global Cancer Pain Therapeutics Revenue by Application (2019-2030)
5.2.1 Global Cancer Pain Therapeutics Revenue by Application (2019-2024)
5.2.2 Global Cancer Pain Therapeutics Revenue by Application (2025-2030)
5.2.3 Global Cancer Pain Therapeutics Revenue Market Share by Application (2019-2030)
5.3 Global Cancer Pain Therapeutics Price by Application (2019-2030)
6 Key Companies Profiled
6.1 BioDelivery Science
6.1.1 BioDelivery Science Corporation Information
6.1.2 BioDelivery Science Description and Business Overview
6.1.3 BioDelivery Science Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.1.4 BioDelivery Science Cancer Pain Therapeutics Product Portfolio
6.1.5 BioDelivery Science Recent Developments/Updates
6.2 ProStrakan Group
6.2.1 ProStrakan Group Corporation Information
6.2.2 ProStrakan Group Description and Business Overview
6.2.3 ProStrakan Group Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.2.4 ProStrakan Group Cancer Pain Therapeutics Product Portfolio
6.2.5 ProStrakan Group Recent Developments/Updates
6.3 Teva pharmaceuticals
6.3.1 Teva pharmaceuticals Corporation Information
6.3.2 Teva pharmaceuticals Description and Business Overview
6.3.3 Teva pharmaceuticals Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Teva pharmaceuticals Cancer Pain Therapeutics Product Portfolio
6.3.5 Teva pharmaceuticals Recent Developments/Updates
6.4 Eli-Lilly
6.4.1 Eli-Lilly Corporation Information
6.4.2 Eli-Lilly Description and Business Overview
6.4.3 Eli-Lilly Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Eli-Lilly Cancer Pain Therapeutics Product Portfolio
6.4.5 Eli-Lilly Recent Developments/Updates
6.5 Grunenthal Group
6.5.1 Grunenthal Group Corporation Information
6.5.2 Grunenthal Group Description and Business Overview
6.5.3 Grunenthal Group Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Grunenthal Group Cancer Pain Therapeutics Product Portfolio
6.5.5 Grunenthal Group Recent Developments/Updates
6.6 GW Pharmaceuticals
6.6.1 GW Pharmaceuticals Corporation Information
6.6.2 GW Pharmaceuticals Description and Business Overview
6.6.3 GW Pharmaceuticals Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GW Pharmaceuticals Cancer Pain Therapeutics Product Portfolio
6.6.5 GW Pharmaceuticals Recent Developments/Updates
6.7 Johnson＆Johnson
6.6.1 Johnson＆Johnson Corporation Information
6.6.2 Johnson＆Johnson Description and Business Overview
6.6.3 Johnson＆Johnson Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Johnson＆Johnson Cancer Pain Therapeutics Product Portfolio
6.7.5 Johnson＆Johnson Recent Developments/Updates
6.8 Meda Pharmaceuticals
6.8.1 Meda Pharmaceuticals Corporation Information
6.8.2 Meda Pharmaceuticals Description and Business Overview
6.8.3 Meda Pharmaceuticals Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Meda Pharmaceuticals Cancer Pain Therapeutics Product Portfolio
6.8.5 Meda Pharmaceuticals Recent Developments/Updates
6.9 Orexo
6.9.1 Orexo Corporation Information
6.9.2 Orexo Description and Business Overview
6.9.3 Orexo Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Orexo Cancer Pain Therapeutics Product Portfolio
6.9.5 Orexo Recent Developments/Updates
6.10 Sanofi
6.10.1 Sanofi Corporation Information
6.10.2 Sanofi Description and Business Overview
6.10.3 Sanofi Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sanofi Cancer Pain Therapeutics Product Portfolio
6.10.5 Sanofi Recent Developments/Updates
6.11 WEX Pharmaceuticals
6.11.1 WEX Pharmaceuticals Corporation Information
6.11.2 WEX Pharmaceuticals Cancer Pain Therapeutics Description and Business Overview
6.11.3 WEX Pharmaceuticals Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.11.4 WEX Pharmaceuticals Cancer Pain Therapeutics Product Portfolio
6.11.5 WEX Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cancer Pain Therapeutics Industry Chain Analysis
7.2 Cancer Pain Therapeutics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cancer Pain Therapeutics Production Mode & Process
7.4 Cancer Pain Therapeutics Sales and Marketing
7.4.1 Cancer Pain Therapeutics Sales Channels
7.4.2 Cancer Pain Therapeutics Distributors
7.5 Cancer Pain Therapeutics Customers
8 Cancer Pain Therapeutics Market Dynamics
8.1 Cancer Pain Therapeutics Industry Trends
8.2 Cancer Pain Therapeutics Market Drivers
8.3 Cancer Pain Therapeutics Market Challenges
8.4 Cancer Pain Therapeutics Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
